10-13-2017 09:52 AM CET - Health & Medicine
Print

Latest Report On Binge Eating Disorder - Pipeline Review, H2 2017

Press release from: MarketResearchReports.biz

"The Report Binge Eating Disorder - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H2 2017, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape.

Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase your risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that eating behavior is out of control and experiencing depression and anxiety. Treatment includes psychotherapy, medications and behavioral weight-loss programs.

Get Sample Copy Of This Report @
www.marketresearchreports.biz/sample/sample/1343257

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Binge Eating Disorder - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 2 and 6 respectively.

Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

View Report @ www.marketresearchreports.biz/reports/1343257/binge-eatin...

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Binge Eating Disorder (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Binge Eating Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Binge Eating Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Binge Eating Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Binge Eating Disorder (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Binge Eating Disorder (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Binge Eating Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Binge Eating Disorder - Overview
Binge Eating Disorder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Binge Eating Disorder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Binge Eating Disorder - Companies Involved in Therapeutics Development
Chronos Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Heptares Therapeutics Ltd
Highland Therapeutics Inc
India Globalization Capital Inc
Novo Nordisk AS
Omeros Corp
Opiant Pharmaceuticals Inc
Shire Plc
Sunovion Pharmaceuticals Inc
Binge Eating Disorder - Drug Profiles
amphetamine MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasotraline hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IGC-504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lisdexamfetamine dimesylate - Drug Profile
Product Description

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz

This release was published on openPR.
News-ID: 772000 • Views: 221
More releases More releases
Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.

You can edit or delete your press release here: